Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nkarta, Inc. (NASDAQ: NKTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nkarta is a clinical-stage biotechnology and biopharmaceutical company developing engineered, allogeneic, off-the-shelf NK cell therapies for autoimmune diseases, and its SEC filings offer structured insight into how it reports financial results, clinical progress, and key risks to investors.
Nkarta’s recent Form 8-K filings include press releases announcing quarterly financial results, where the company discusses research and development expenses, general and administrative expenses, net loss, and its cash position. These 8-Ks also reference Nkarta’s status as an emerging growth company and point to more detailed risk factor sections in its Form 10-K and Form 10-Q reports.
Through its periodic filings, Nkarta describes the clinical development of its lead NK cell therapy candidate NKX019, including its use in Ntrust-1 and Ntrust-2 autoimmune disease trials and investigator-sponsored studies. The company’s filings outline factors such as limited operating history, lack of approved products, dependence on NKX019, clinical trial timing, manufacturing complexity for CAR NK therapies, and reliance on third parties, which it identifies as key business and development risks.
On Stock Titan, Nkarta’s SEC filings are updated as new documents are posted to the EDGAR system. AI-powered summaries help explain the main points of lengthy filings, highlight changes from prior reports, and surface items such as financial condition discussions and risk factor updates. Users can quickly review 8-Ks related to earnings announcements and use the platform’s tools to understand how Nkarta’s disclosures connect to its NK cell therapy pipeline and autoimmune disease focus.
Tang Capital Management and related entities filed Amendment No. 2 to a Schedule 13G reporting their beneficial ownership in Nkarta, Inc. common stock. They report beneficial ownership of 1,480,823 shares, representing 2.1% of Nkarta’s common stock, based on 71,029,512 shares outstanding as of November 5, 2025. The shares are held with no sole voting or dispositive power and with shared voting and dispositive power over 1,480,823 shares across Tang Capital Management, Tang Capital Partners, Tang Capital Partners International and Kevin Tang. The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of Nkarta, indicating a passive investment stance and confirming ownership of 5% or less of the class.
Nkarta, Inc. insider transaction: Chief Executive Officer and director Paul J. Hastings reported an automatic sale of 26,046 shares of Nkarta common stock on 01/15/2026 at a price of $2.07 per share. The filing explains that these shares were sold to satisfy tax withholding obligations arising from the vesting and settlement of Restricted Stock Units and that the transaction was not a discretionary trade by the reporting person. Following this tax-related sale, Hastings beneficially owned 390,023 shares of Nkarta common stock directly.
Nkarta, Inc. (NKTX) president Mahmood Nadir reported a small sale of company stock related to tax withholding. On January 15, 2026, he sold 5,649 shares of Common Stock at $2.07 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, and were not a discretionary sale. After this transaction, he directly beneficially owned 167,727 shares of Nkarta common stock.
Nkarta, Inc. insider Rose Shawn Marshall, the company’s Chief Medical Officer and Head of Research & Development, reported new equity awards on a Form 4. On January 6, 2026, Marshall received 70,000 shares of Common Stock in the form of Restricted Stock Units, granted at $0 per share. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU representing one share of Nkarta common stock.
On the same date, Marshall was also granted a stock option to buy 139,000 shares of Common Stock at an exercise price of $1.93 per share. This option is scheduled to vest in 48 equal monthly installments, based on continued service after January 14, 2026, and expires on January 5, 2036. Both awards are reported as directly owned following these transactions.
Nkarta, Inc. reported an equity award to its President, Mahmood Nadir, in the form of both restricted stock units and stock options. On 01/06/2026, he received 80,000 shares of Common Stock as Restricted Stock Units, which are scheduled to vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock.
On the same date, he was also granted a stock option covering 160,000 shares of Common Stock at an exercise price of
Nkarta, Inc. reported an insider equity award for Chief Executive Officer and director Paul J. Hastings. On January 6, 2026, he received 94,000 shares of Common Stock in the form of Restricted Stock Units, granted at a price of $0. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU convertible into one share of Common Stock.
On the same date, Hastings was also granted a stock option for 562,000 shares of Common Stock at an exercise price of $1.93 per share, with no cost reported for the grant itself. This option is scheduled to vest in 48 equal monthly installments following January 14, 2026. After these transactions, he beneficially owned 416,069 shares of Common Stock directly, along with the 562,000 stock options. The share total includes 2,000 shares acquired under Nkarta’s 2020 Employee Stock Purchase Plan on November 30, 2025.
Nkarta, Inc. reported Q3 2025 results. Net loss was
Balance sheet and liquidity. Cash, cash equivalents, restricted cash and investments totaled
Nkarta, Inc. furnished an update on its business by announcing that it issued a press release with financial results for the third quarter ended September 30, 2025. The company provided this update via a current report and attached the press release as Exhibit 99.1 titled “Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights.”
The disclosure states that the information, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf engineered NK cell therapies, with lead program NKX019 targeting CD19 for autoimmune diseases. The company continues multiple Phase 1 and investigator-sponsored trials while reprioritizing its pipeline and modifying lymphodepleting conditioning for ongoing studies.
For the three months ended June 30, 2025 Nkarta reported a net loss of $22.98 million and for the six months a net loss of $54.96 million. Research and development was $20.78 million in the quarter and $44.95 million for six months; total operating expenses were $27.19 million in the quarter. As of June 30, 2025 the company had an accumulated deficit of $599.2 million and reported $334.0 million of cash, cash equivalents, restricted cash and investments, which management believes is sufficient to fund operations for at least 12 months.
Operational actions include a March 26, 2025 reduction in force of 53 positions (~34% of workforce) with related severance of approximately $5.4 million, deprioritization of certain programs, and the appointment of Shawn Rose, M.D., Ph.D., as Chief Medical Officer effective June 23, 2025. The balance sheet shows total assets of $448.3 million and operating lease liabilities of $78.5 million.
Nkarta, Inc. furnished a press release announcing its financial results for the second quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Current Report on Form 8-K. The Form 8-K also includes a Cover Page Interactive Data File as Exhibit 104. The filing states the Item 2.02 disclosure (including Exhibit 99.1) is being furnished and shall not be deemed "filed" under the Exchange Act nor incorporated by reference into filings under the Securities Act or the Exchange Act unless the company expressly states otherwise.
The filing identifies the registrant as a Delaware corporation (Commission File Number 001-39370; EIN 47-4515206), lists its principal executive office in South San Francisco, California, and shows the company’s common stock trades as NKTX on the Nasdaq Global Select Market. The report is signed by Nadir Mahmood as President.